Hubertus von Baumbach
Missing a competitor? Contribute!
Bayer is the top competitor of Boehringer Ingelheim. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, and was founded in 1863. Bayer competes in the Medical Research & Laboratories field. Bayer generates 178% the revenue of Boehringer Ingelheim.
Merck KGaA is perceived as one of Boehringer Ingelheim's biggest rivals. Merck KGaA was founded in Darmstadt, Other} in 1668. Like Boehringer Ingelheim, Merck KGaA also operates in the Pharmaceuticals industry. Compared to Boehringer Ingelheim, Merck KGaA generates $7B less revenue.
Sanofi is seen as one of Boehringer Ingelheim's top competitors. Sanofi is a Public company that was founded in Paris, Île-de-France in 1994. Like Boehringer Ingelheim, Sanofi also works within the Pharmaceuticals industry. Sanofi has 47,468 more employees vs. Boehringer Ingelheim.
Weigh-in!Help the Owler community know more
Growth Score - 1/1
Is $28.6B a good estimate for Boehringer Ingelheim's revenue?
Trending News for Boehringer Ingelheim and Boehringer Ingelheim's Competitors
Boehringer Ingelheim Acquisitions
NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer.
Labor Dr. Merk & Kollegen GmbH
LaborDr.Merk is a biotechnology firm that develops and commercializes oncolytic viral therapeutics for the treatment of cancer.
Global Stem cell Technology NV
GST is a biotechnology company that develops blood-derived mesenchymal stem cells to treat orthopedic and metabolic diseases in animals.
Northern Biologics, Inc.
Northern Biologics designs and develops antibody therapeutics for oncology treatments.
Amal Therapeutics SA
Amal Therapeutics develops and commercializes peptide-based therapeutic vaccines for the treatment of cancer.
These are all the companies that Boehringer Ingelheim has acquired. Boehringer Ingelheim has acquired 9 companies and its latest acquisition was NBE-Therapeutics AG in Dec 2020. NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer.
Boehringer Ingelheim Funding History
No recent funding data found related to Boehringer Ingelheim
Boehringer Ingelheim Investments
These are all the companies that Boehringer Ingelheim has invested in. Boehringer Ingelheim has invested 9 companies and its latest investment was NBE-Therapeutics AG in Dec 2020. NBE Therapeutics is a biotechnology company that develops and commercializes antibody-drug conjugates for the treatment of cancer.
Boehringer Ingelheim News
June 11, 2021PharmiWeb
Boehringer Ingelheim is a Founding Member of QUTAC
Ten leading German companies form this newly created Quantum Technology and Application Consortium To... See more » June 11, 2021Pharmabiz
Boehringer Ingelheim, Lifebit Biotech partner to detect global infectious disease outbreaks
Boehringer Ingelheim, a global leader in animal health, announces the beginning of a long─term partne... See more » May 28, 2021MarketScreener
Boehringer's BI 425809 has potential to address cognitive impairment in schizophrenia market, says GlobalData
(marketscreener.com) 28 May 2021 Boehringer's BI 425809 has potential to address cognitive impairment... See more » May 27, 2021Manufacturing Chemist
Novatek requalifies as Boehringer Ingelheim approved supplier
The companyâ€ s products are designed to assist in managing critical aspects of a quality-controlled ... See more » May 27, 2021BW BUSINESSWORLD
Lupin Receives USD 50 Million From Boehringer Ingelheim For Achievement Of Key Milestones
Lupin said its new chemical entity research team is focused on building a pipeline of highly differen... See more » May 26, 2021BW BUSINESSWORLD
Boehringer Ingelheim India Launches Single-Shot Poultry Vaccine In India
The VAXXITEK HVT+IBD vaccine protects against two major immunosuppressive diseases -- Infectious Burs... See more »
Boehringer Ingelheim Blogs
Boehringer Ingelheim Press Releases
Boehringer Ingelheim Videos
Boehringer Ingelheim Headquarters
Boehringer Ingelheim Summary
Boehringer Ingelheim is a pharmaceutical company that develops, manufactures and commercializes prescription medicines and animal healthcare products. Boehringer Ingelheim was founded in 1885. Boehringer Ingelheim's headquarters is located in Ingelhei... Boehringer Ingelheim's Chairman, Hubertus von Baumbach, currently has an approval
rating of 76%. Boehringer Ingelheim's primary competitors are Bayer, Merck KGaA & Sanofi.
Frequently Asked Questions about Boehringer Ingelheim
When was Boehringer Ingelheim founded?Boehringer Ingelheim was founded in 1885
Who is Boehringer Ingelheim's CEO?Boehringer Ingelheim's CEO is Hubertus von Baumbach
How much revenue does Boehringer Ingelheim generate?Boehringer Ingelheim generates $28.6B in revenue
How much funding does Boehringer Ingelheim have?Boehringer Ingelheim has historically raised $0 in funding
Where is Boehringer Ingelheim's headquarters?Boehringer Ingelheim's headquarters is in Ingelheim am Rhein Rhineland-Palatinate, DE
How many employees does Boehringer Ingelheim have?Boehringer Ingelheim has 51,944 employees
What sector does Boehringer Ingelheim operate in?Boehringer Ingelheim is in Pharmaceuticals
Who are Boehringer Ingelheim's competitors?Boehringer Ingelheim's top competitors are Bayer, Merck KGaA, Sanofi
Who has Boehringer Ingelheim invested in?Boehringer Ingelheim's has invested in companies such as Actym Therapeutics, HepaRegeniX, Eyevensys